Systemic treatment for BRAF-mutant melanoma: where do we go next? (Q38235584)

31 August 2017

title

Systemic treatment for BRAF-mutant melanoma: where do we go next? (English)

1 reference

31 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079100%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Georgina V. Long

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079100%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

2

Georgina V Long

1 reference

31 August 2017

1

Alexander M Menzies

1 reference

31 August 2017

publication date

1 August 2014

1 reference

Lancet Oncology Commission

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079100%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079100%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079100%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

e371-81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079100%20AND%20SRC:MED&resulttype=core&format=json

Which drug, and when, for patients with BRAF-mutant melanoma?

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Paradoxical oncogenesis: are all BRAF inhibitors equal?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Ultraviolet A and photosensitivity during vemurafenib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Hepatotoxicity with combination of vemurafenib and ipilimumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Evolutionary dynamics of cancer in response to targeted combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

NRAS mutation status is an independent prognostic factor in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Prognostic factors for survival in melanoma patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

BRAF inhibitor activity in V600R metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970072-5

7 January 2021

10.1016/S1470-2045(14)70072-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079100%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference